In Vivo

Show me the money

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

By Anil Shrivastava, David Bellaire and Ashish Singh

First published on septiembre 01, 2005
min read


Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues. Download the Full Report (pdf)